What characteristics are needed to be a good candidate for cross-linking for keratoconus?

Click here to read the Cover Story to this Point/Counter.

Corneal collagen cross-linking is a treatment designed primarily to decrease the progression of keratoconus. Indeed, the FDA-approved indication is for progressive keratoconus in patients 14 years of age or older. This was based on a randomized controlled clinical trial that we recently published. Therefore, the best candidate for cross-linking is a patient with documented progression of disease. This documentation is based on clinical discretion. For instance, serial corneal topography may show an increase in the keratoconus cone.

Full Story →